| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13G · 5 securities · passive | ||||||
|
enVVeno Medical Corporation
13G/A
NVNO · 29415J205
|
5.5% |
5/15/2026
Event 3/31/2026
|
||||
| Kingdon Capital Management, L.L.C. | 5.5% | |||||
| M. Kingdon Offshore Master Fund, L.P. | 5.5% | |||||
| Kingdon GP, LLC | 5.5% | |||||
| Mark Kingdon | 5.5% | |||||
|
SCYNEXIS, Inc.
13G/A
SCYX · 811292200
|
0% |
2/17/2026
Event 12/31/2025
|
||||
| Kingdon Capital Management, L.L.C. | 0% | |||||
| Mark Kingdon | 0% | |||||
|
Jasper Therapeutics, Inc.
13G/A
JSPR · 471871202
|
4.7% |
11/12/2025
Event 9/30/2025
|
||||
| Kingdon Capital Management, L.L.C. | 4.7% | |||||
| Mark Kingdon | 4.7% | |||||
|
enVVeno Medical Corporation
13G
NVNO · 29415J106
|
7.1% |
9/9/2025
Event 9/2/2025
|
||||
| Kingdon Capital Management, L.L.C. | 7.1% | |||||
| M. Kingdon Offshore Master Fund, L.P. | 6.6% | |||||
| Kingdon GP, LLC | 6.6% | |||||
| Mark Kingdon | 7.1% | |||||
|
OptiNose, Inc.
13G
OPTN · 68404V209
|
5.1% |
4/14/2025
Event 4/9/2025
|
||||
| Kingdon Capital Management, L.L.C. | 5.1% | |||||
| Mark Kingdon | 5.1% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.